during conditioning, reflecting amphotericin-nephrotoxicity) and rabbit antithymocyte globulin (ATG-Fresenius, 120 mg/kg). For GVHD prophylaxis, he received MTX and CsA. Before engraftment, six units of Kell-negative packed RBC (PRBC) were given. He was discharged on day 30 on CsA without signs of GVHD.
On day 100, full chimerism was demonstrated by informative microsatellite DNA markers. Leukocytes were 4.8 Â 10 9 /l, hemoglobin 10 g per 100 ml and platelets 90 Â 10 9 /l. CsA was stopped. After a cold, he was admitted on day 132 with acute warm-type hemolytic anemia (hemoglobin 2.8 g per 100 ml). Free and erythrocyte-bound antibodies of indeterminable specificity were present and direct antiglobulin test was positive with IgG, IgA, IGM, C3d and C3c. The eluate was pan reactive, most likely against anti-Kx and anti-Kell. Throughout the next 2.5 years, severe and at times life-threatening hemolysis necessitated frequent transfusions (720 cc PRBC/kg body weight/year) and iron chelation. Leukocytes and platelet counts were normal.
Two transfusion-free intervals of around 100 days were maintained with intravenous immunoglobulin and prednisone, each followed by the progression of massive hemolysis (157 PRBC in 10 months and 94 PRBC in 11 months). Additional interventions during the first progression included 3 months of azathioprine (started 10 months before the second remission), four doses rituximab (8 months before the second remission), four doses VCR (7 months before the second remission), splenectomy (3 months before the second remission), CsA (3 months before the second remission) and three monthly DLIs escalating up to 3 Â 10 5 CD3 þ /kg (3 months before the second remission). Interventions during the second progression included two more DLIs (4 Â 10 6 and 5 Â 10 7 CD3 þ /kg). The last dose (day 945) achieved a continuous remission of hemolysis within weeks, even before Glucksberg overall grade II GVHD (skin stage III) occurred, responsive to mycophenolate mofetil and CsA discontinued 4 months later.
Semiquantitative lineage-specific chimerism was assessed by PCR analysis of informative minisatellite markers of Dynabead-separated T, B and myeloid cells.
1 At presentation of hemolysis, 33% of CD3, CD4 and CD8 cells and 100% of CD19, CD14/15 and CD34 cells were of donor origin . CD8 donor chimerism reached nadir at 8% and remained below 50% until the last DLI, shortly after which there was full conversion for all cells. Before conversion, the mean donor chimerism was 39% for CD3, 38% for CD4, 24% for CD8, 87% for CD19 and 100% for CD14/ 15 and CD34 cells. Residual nucleated cells (including normoblasts and reticulocytes) showed 490% donor chimerism, indicating blood group conversion. At times of dramatic hemolysis, CD8 donor chimerism was o30% in contrast to CD19 donor chimerism 490%. Currently, 9 years after transplant, he has stable full chimerism in all lineages with normal neutrophil oxidase capacity and no hemolysis.
Post transplant, early-onset acute alloimmune hemolysis has to be separated from the late-onset chronic immune hemolysis. The former occurs when isohemagglutinins produced by immunocompetent donor B-lymphocytes hemolyse recipient erythrocytes in minor or bidirectional ABO mismatches ('passenger lymphocyte syndrome', also seen in solid organ transplant). Late-onset autoimmune hemolysis (AIHA) usually reflects a donor autoimmune response against donor erythrocytes, irrespective of ABO constellation, and is less well understood. It may be due to homeostatic expansion of surviving autoreactive recipient T-cell clones, 2 or loss of self-tolerance through depletion of CD4 þ CD25 þ T regulatory cells by anti-GVHD medication or GVHD itself. 3 Chronic hemolysis post transplant may also be alloimmune if there is mixed chimerism and blood group disparity, the significance depending on the antibody, and rarely as severe as in our case.
Autoimmune hemolysis is reported [4] [5] [6] [7] [8] to occur at a median of 7 months post transplant, 40/56 AIHA were of warm-type IgG, remission of hemolysis was reported in only 16 patients (pharmacological treatment [4] [5] [6] [7] [8] ) and in six patients who received a second hematopoietic SCT or DLI 4, 8 for disease relapse or graft failure. AIHA occurred exclusively 4, 5, 8 or preferentially 6, 7 in unrelated hematopoietic SCT. Children o10 years and children transplanted for metabolic disorders had an increased risk for AIHA, 4 as had adults with extensive chronic GVHD, 5,7 whereas T-cell depletion, ABO mismatch and CMV status were not risk factors. Interestingly, 6/9 transplanted CML patients suffered a leukemic relapse concurrently with AIHA, 4/4 tested showed mixed chimerism and 3/5 had a second remission with DLI and were cured of AIHA with conversion to full chimerism. 8 Split-mixed chimerism of donor T lymphocytes in our case correlated with alloimmune hemolytic anemia. Persisting alloreactive recipient T cells primed against Kx were boosted by donor erythropoiesis and transfused erythrocytes, mounting a strong alloimmune response of the very few remaining recipient plasma cells. Subversion of the prevailing donor B-cells through host T cells into an autoimmune reaction cannot be ruled out. Indeed, AIHA may complicate alloimmune hemolysis even after full conversion, 9 and it can be induced experimentally by alloimmune hemolysis in a mouse model. 
